Key Takeaways for 2026 Sellers
- The 2026 dental-practice transition market offers two main exit paths, doctor-to-doctor sales or DSO/private-equity affiliation, and the broker you choose can strongly influence value and deal structure.
- Without competitive tension from multiple qualified buyers, sellers can lose 20–30% of practice value; McLerran’s structured auction process typically generates about 10 offers per listing.
- Complex DSO deals often involve multi-year financial forecasting and careful buyer vetting to protect both cash at close and long-term equity; McLerran models each path across 3-, 5-, 7-, and 10-year timelines.
- McLerran & Associates reports an 85–90% transaction rate, more than double the industry norm, after closing nearly 2,000 sales representing nearly $2 billion in volume.
- Owners of premier practices who are ready to explore either transition path can schedule a confidential discovery call with McLerran & Associates to receive a diligence-grade valuation and side-by-side comparison of their options.
The 2026 Dental-Practice Transition Landscape
Dental practice ownership has shifted over the past decade as private-equity-backed DSOs have brought institutional capital, experienced negotiating teams, and complex deal structures into a market that was once almost entirely doctor-to-doctor. The American Dental Association reports that 16.1% of U.S. dentists were affiliated with a dental support organization as of 2024, and 69% of DSOs indicate their private equity sponsors expect a moderate or high increase in acquisition activity in 2026.
At the same time, the traditional doctor-to-doctor exit path has eroded due to structural decline in practice ownership among younger dentists, and the average retirement age for U.S. dentists reached 68.7 years in 2024, so a large cohort of owners is approaching transition at the same time. A practice owner sells once in a lifetime, while a DSO negotiates deals every week. That information gap, combined with a fragile deal process that can collapse at several points, can make professional, dental-specific sell-side representation feel essential for many owners. Before engaging that representation, owners benefit from understanding the main exit paths available.
Choosing Between Private Buyer and DSO Paths
The first step in any transition is to identify which path, or combination of paths, fits the practice and the owner’s goals. Two primary routes exist.
Doctor-to-doctor (private buyer) sales are most common for premier practices generating roughly $1 million to $1.5 million in annual revenue. Private-sale general dental practices typically transact at 65–85% of annual gross collections, with the buyer usually being another dentist financed through a bank or SBA loan. The structure is straightforward. The buyer pays 100% of the agreed price at closing, with no earnouts or retained equity. The seller typically works back four to eight weeks and then exits.
DSO and private equity affiliation can fit practices generating $1.5 million or more in revenue. DSO buyers value practices using EBITDA multiples. EBITDA, or earnings before interest, taxes, depreciation, and amortization, is essentially the practice’s operating profit after replacing the owner’s compensation with a market-rate associate salary. These deals often structure 60–80% of total consideration as cash at closing, with the remainder in earnouts or equity rollover. Up to 40% of a DSO deal can be paid in equity rather than cash, so the owner also becomes an investor in the DSO platform and may want to evaluate that investment carefully.
McLerran & Associates works both paths in roughly equal measure, a genuine 50/50 split. The firm produces a side-by-side valuation for owners in the $1.5 million to $3 million revenue range who can realistically pursue either option. That comparison, grounded in a CPA-led EBITDA analysis, can replace guesswork with data.
Talk with a McLerran advisor to see how a private-buyer sale and a DSO affiliation could compare for your practice.
Creating Real Buyer Competition
Owners who negotiate with a single buyer often give up leverage and value. Without competitive tension, meaning multiple qualified buyers bidding at the same time, there is no true market, only a negotiation that the buyer largely controls. Unrepresented healthcare practice sellers can lose an estimated 20–30% of practice value due to limited buyer exposure alone.
McLerran & Associates addresses this risk through a structured, auction-style bid process that typically runs 45 to 60 days and generates around 10 offers per listing. The firm builds a marketing deck and a virtual data room, which is a comprehensive, organized collection of financial and operational documents worth showcasing. It then solicits offers from a vetted pool of well-qualified buyers. Poorly run DSOs are blacklisted before the process begins, so owners interact only with credible counterparties. The process narrows from initial offers to in-person meetings with the top one to three finalists, which helps preserve competitive tension through the final negotiation.
Practices that go to market with structured representation often receive multiple offers, which can support higher final transaction values. McLerran clients typically see about a 30% increase in valuation compared with selling alone, a result that stems from creating competition rather than accepting the first offer on the table.
Evaluating Buyer Fit and Deal Structure
The highest bidder does not always represent the best long-term partner. A DSO deal that looks attractive on headline price can look different after the equity component is stress-tested, the earnout terms are examined, and the DSO’s financial health is reviewed. DSO offers frequently include rollover equity, earnouts, seller notes, escrows, holdbacks, working-capital targets, purchase-price adjustments, employment terms, and non-compete obligations, which can make DSO affiliation structures more complex than standard private-buyer asset sales.
McLerran & Associates responds to this complexity with multi-year, multi-structure financial forecasting. The firm models what each path could net the owner over 3-, 5-, 7-, and 10-year horizons. These models compare cash at close, equity distributions, and earnout scenarios side by side, including the baseline of keeping the practice and taking distributions. Equity in a DSO deal can be held at the joint-venture level, with ongoing distributions and a higher floor but lower ceiling, or at the holding-company level, with no distributions but a higher ceiling that can multiply upon recapitalization. That distinction can materially change the long-term economic outcome and often merits careful analysis.
The firm also vets buyers in a way similar to how an investor might vet a stock. The team reviews whether the DSO is profitable across its existing locations, whether revenue is still growing, whether the management team is experienced, and whether the private equity backer has completed similar transactions successfully. Owners are guided toward well-backed, well-run partners with a track record of satisfied sellers and away from undercapitalized buyers whose equity could be at greater risk.
Examples of Outcomes for Premier Practices
Maximizing outcome can mean protecting both the financial result and the legacy, including staff, patients, and practice culture. McLerran & Associates has closed approximately 2,000 successful practice sales representing nearly $2 billion in transaction volume, with an 85–90% transaction rate among its clients. That rate compares with an industry norm closer to 35–40% and a do-it-yourself close rate of roughly 15–20%.
Three anonymized examples illustrate the range of outcomes that this type of process can support.
- A multi-doctor practice that had grown beyond what any single private buyer could finance went to market through a structured DSO bid process. Eight offers came in, and the owners used competitive tension to strengthen value while selecting a buyer they genuinely wanted as a partner.
- A pediatric group owner with seven locations had existing DSO offers on the table when he engaged McLerran. After a CPA-led EBITDA analysis that clarified the practice’s true profitability, the final valuation came in about 20% higher than the offers already presented.
- A solo practitioner who had built one of the premier practices in his market over more than 40 years wanted to protect his legacy without fully retiring. McLerran generated six offers from vetted buyers, and the owner chose the partner who best fit his goals for staff and patient continuity while still achieving a strong financial result.
How Broker Models Compare for Sellers
Dental practice brokers do not all operate the same way. The table below compares five common models across six dimensions that can directly affect seller outcomes. Every figure is drawn from cited sources.
| Dimension | DIY / FSBO | Local Generalist Broker | Multi-Vertical Advisor | “Free Valuation” Firm | McLerran & Associates |
|---|---|---|---|---|---|
| Dental specialization | None | Local only | Spread across verticals | Varies | Dental-only, national depth |
| Both sale paths | No | Usually one | Sometimes | Usually one | Both private-buyer & DSO, ~50/50 |
| Valuation quality | Buyer-set | Weak | Variable | Free / lead-gen anchor | CPA-led, diligence-grade |
| Buyer pool | One buyer; ~50% of unrepresented sales fail to close | 1–2 DSOs / small list | Generic list | Partial list | Largest premier pool; vetted & blacklisted DSOs |
| Competitive tension | None | Minimal | Some | Low | Structured auction, multiple offers |
| Transaction rate | ~15–20% (DIY) | Below average | Variable | ~35–40% (industry norm) | ~85–90% |
Why a Paid, Diligence-Grade Valuation Matters
Many owners want clarity on broker fees and valuation quality. Most dental practice brokers charge a success-based commission, typically 8–12% of the total transaction value, paid by the seller at closing. Some firms offer a free valuation as a lead-generation tool, then use that number as the anchor for the entire transaction.
The main concern with a free valuation is often quality rather than price. A quick estimate that has not been built from the ground up using normalized EBITDA, verified add-backs, and a defensible methodology can be challenged during buyer due diligence. When that happens, the deal can be re-traded downward, sometimes by hundreds of thousands of dollars. Practices sold with professional broker representation can sell for more than those sold independently, even after accounting for broker fees.
McLerran & Associates charges for its valuation because the work is diligence-grade, meaning a CPA-led EBITDA analysis that is designed to hold up when a buyer’s quality-of-earnings team reviews every line. The firm’s position is clear: the team focuses on selling practices, not simply listing them. If an owner is not ready to sell after the valuation is complete, McLerran will update it for free a year later.
Request a diligence-grade valuation to see what your practice could command in today’s market.
Regional Reach and Local Market Insight
McLerran & Associates operates nationally, with dedicated offices covering major markets across the United States.
- Midwest / Cleveland: Justin Klingshim leads the Cleveland office, with recent closings across Ohio.
- Southeast / Atlanta: Matt Sutton leads the Atlanta office, which also covers the Southwest.
- Mid-Atlantic / Northern Virginia: Andrew Kobylski leads the Northern Virginia office.
- West Coast / Los Angeles: Steven Au leads the Los Angeles office.
- Mountain West / Phoenix: Brian Carroll leads the Phoenix office, covering the broader Mountain West region.
This geographic footprint helps the firm understand how valuations, buyer appetite, and achievable cash at close can vary by market. Some states now have more than 40% of their active dentists aged 55 and older, which creates concentrated seller supply in certain regions and makes local market intelligence a meaningful factor in timing and positioning a listing.
How to Choose a Dental Practice Broker
Owners evaluating dental practice transition consultants and sell-side advisors can use the following criteria to assess fit and capability.
- Dental-only focus. A broker who works across multiple healthcare or business verticals may struggle to build the specialty-by-specialty buyer relationships, valuation nuance, and DSO market insight that a dental-only firm can develop over decades. That depth of specialization often supports stronger positioning.
- Both transition paths. An advisor who works only doctor-to-doctor deals or only DSO deals may not provide an unbiased side-by-side comparison. Confirm the firm’s actual transaction split between the two paths so you can see whether both routes are used in practice.
- Valuation methodology. Ask whether the valuation is CPA-led, whether it normalizes EBITDA with documented add-backs, and whether it has held up through buyer due diligence without re-trading. Free valuations can be a red flag when they are used mainly as marketing tools.
- Buyer pool size and vetting. Ask how many buyers are in the firm’s active pool, how they are pre-qualified, and whether any buyers have been blacklisted for poor post-close behavior. A curated pool can save time and reduce risk.
- Transaction rate. Legitimate dental M&A advisors can often report strong success rates when asked during the advisor selection process. McLerran & Associates reports an 85–90% transaction rate, well above the industry norm of 35–40%.
- Sell-side only. Confirm that the advisor never represents the buyer. Dual representation can create conflicts of interest that may disadvantage the seller.
- Track record and references. Ask for anonymized case studies and, when possible, references from sellers in similar practice types and revenue ranges. These conversations can provide practical insight into how the process feels.
Conclusion: Preparing for a 2026 Practice Sale
The 2026 dental practice transition market tends to reward owners who enter it with a dental-specific sell-side advisor, a diligence-grade valuation, and a structured process that creates real competition among well-qualified buyers. The firm’s results, including the transaction rate and volume cited earlier, stem from running both transition paths in roughly equal measure, building a large premier buyer pool, and requiring CPA-led EBITDA work before listing.
For owners of premier dental practices generating $1 million or more in annual revenue, the choice of sell-side advisor can be one of the most consequential decisions of the entire transition. Effective dental practice brokers are often the ones whose process, buyer relationships, and advocacy help produce outcomes that hold up from first offer through final closing, rather than the ones who provide the fastest free valuation.
Frequently Asked Questions
What is the difference between a dental practice broker and a dental practice transition consultant?
The terms are often used interchangeably, but there can be meaningful differences in scope. A dental practice broker typically focuses on listing a practice, finding a buyer, and facilitating the transaction, similar to a real estate agent. A dental practice transition consultant, or sell-side M&A advisor, usually provides a broader range of services, including a comprehensive EBITDA-based valuation, financial forecasting across multiple deal structures, competitive bid management, negotiation of the letter of intent, quality-of-earnings support through due diligence, and advocacy through closing. For owners of premier practices generating $1 million or more in annual revenue, where deal structures can include cash, equity rollover, and earnouts, this deeper advisory model can be one of the main factors supporting stronger outcomes. McLerran & Associates operates as a full sell-side advisor and advocate, not simply a listing agent.
How much do dental practice brokers charge, and is a paid valuation worth it?
Most dental practice brokers charge a success-based commission of roughly 8–12% of the final transaction value, paid by the seller at closing. Some firms also charge a smaller upfront listing or marketing fee. Firms that offer free valuations typically use that number as a lead-generation tool, and the valuation may be a quick estimate that does not fully reflect normalized EBITDA or withstand buyer due diligence. When a weak valuation is challenged during diligence, the deal can be re-traded downward, which can cost the seller far more than the price of a rigorous upfront analysis. A paid, CPA-led valuation that documents every add-back and is built to withstand scrutiny can be one of the main factors that separates a deal that closes at the agreed price from one that erodes before the finish line. McLerran & Associates charges for its valuation because the work is diligence-grade, and the firm’s position is straightforward: the team focuses on selling practices, not just listing them.
Should I sell my dental practice to a private buyer or affiliate with a DSO?
The right answer depends on the size and profitability of the practice, the owner’s personal and financial goals, and current buyer demand in the specific market. The revenue thresholds described earlier, roughly $1 million to $1.5 million for private buyers and $1.5 million or more for institutional acquirers, provide a starting framework. The decision also depends on how comfortable the owner feels with deal complexity, equity rollover, and post-sale involvement. Owners in the $1.5 million to $3 million revenue range can often pursue either path, and a true side-by-side valuation that quantifies the practice’s worth in both markets can support a more informed choice. Because McLerran & Associates works both paths in roughly equal measure, the firm can produce that comparison without a built-in bias toward either outcome.
What makes a dental practice more or less attractive to DSO and private equity buyers in 2026?
Several factors can influence how DSO and private equity buyers view a dental practice’s value and risk profile. Practices where the owner performs most of the production can face valuation adjustments or heavier earnout requirements, because buyers are acquiring revenue that depends heavily on one person. A diversified provider mix, with associates contributing meaningfully to production, can support stronger offers. Payer mix also matters. Practices with high exposure to government payers may see a more limited buyer pool among institutional acquirers. On the positive side, strong hygiene revenue, a large active patient base, modern technology, and clean, well-organized financials can support higher valuations and smoother due diligence. Specialty can also play a role, with some specialties commanding higher multiples than general dentistry due to their revenue and referral dynamics. For any individual practice, the specific multiple is usually driven by its own numbers and market, which is what a diligence-grade valuation is designed to quantify.
How long does it typically take to sell a dental practice?
Timelines can vary by path and practice complexity. Doctor-to-doctor sales typically take six to ten months from engagement through closing, with the active marketing and negotiation phase running about two to four months. DSO and private equity transactions often take longer, commonly nine to 13 months, because corporate due diligence, quality-of-earnings review, equity rollover documentation, and insurance recredentialing all add time. Owners who begin transition planning several years in advance, ideally three to five years before a target exit, often achieve stronger outcomes because they have time to address factors such as provider concentration, lease terms, and financial documentation that might otherwise slow or derail a deal. McLerran & Associates manages the process from the initial valuation through final closing, with the goal of protecting both timeline and transaction value at each stage.
